Alpha Cognition (ACOG) versus Its Rivals Head-To-Head Review

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Alpha Cognition to related companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Alpha Cognition and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1922	5378	13921	295	2.59

Alpha Cognition presently has a consensus price target of $20.00, indicating a potential upside of 261.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 103.08%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpha Cognition is more favorable than its competitors.

Valuation & Earnings

This table compares Alpha Cognition and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.16
Alpha Cognition Competitors	$574.43 million	-$70.96 million	0.11

Alpha Cognition’s competitors have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 31.5% of Alpha Cognition shares are held by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Alpha Cognition has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s competitors have a beta of -3.86, indicating that their average stock price is 486% less volatile than the S&P 500.

Profitability

This table compares Alpha Cognition and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Alpha Cognition beats its competitors on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.